The research behind the formula
Three of the five actives in LibiTight — hyaluronic acid, chamomile extract, and L-arginine — have been studied in published clinical research for vaginal health. LibiTight combines them in a single non-hormonal topical gel.
How to read this evidence
The studies referenced on this page were each conducted on individual active ingredients — not on the LibiTight formulation. This is the standard structure for published clinical research: trials test discrete molecules at defined concentrations, in defined populations, with defined outcomes.
LibiTight combines three of those studied actives — hyaluronic acid, chamomile extract, and L-arginine — alongside two complementary ingredients (allantoin and potassium alum) in a single topical gel. The studies validate each active's biological activity at clinically relevant concentrations; LibiTight applies that activity in a multi-functional non-hormonal formula.
One important caveat: the L-arginine study referenced uses an oral combination supplement, while LibiTight delivers L-arginine topically. The mechanism is the same — L-arginine supports nitric oxide production, which supports local circulation — but the delivery route differs. The study is included for the mechanism it documents, not as a direct outcome comparison.
Referenced research
Each card links to the published study.
Postmenopausal women experiencing vaginal dryness
Topical hyaluronic acid gel produced significant improvement in dryness symptoms with no reported adverse effects. Participants reported greater moisture and improved comfort during intercourse.
Published in ScienceDirect · S1743609515303994
View studyPostmenopausal women with vaginal atrophy
Hyaluronic acid produced significant improvements in moisture and tissue elasticity, with reductions in atrophy symptoms. No significant adverse effects were reported.
Published in PubMed · PMID 33293236
View studyPostmenopausal women with vulvovaginal atrophy · 8 weeks
Eight weeks of topical hyaluronic acid application improved vaginal health and tissue elasticity. Participants reported enhanced hydration with no adverse effects.
Published in European Review
View studyPostmenopausal women with vaginal atrophy · 12 weeks
In a 12-week comparison, hyaluronic acid vaginal cream performed comparably to conjugated estrogen for improving vaginal health and reducing atrophy symptoms. Participants reported enhanced moisture with no significant adverse effects.
Published in PubMed Central · PMC4709811
View studyPostmenopausal women experiencing painful intercourse · 8 weeks
Eight weeks of chamomile vaginal gel produced significant reduction in pain during intercourse and improvement in intimate comfort. Participants found the treatment well-tolerated, with no significant adverse effects.
Published in PubMed Central · PMC7508318
View studyWomen experiencing intimate health concerns · 4 weeks
In a four-week study, participants taking an L-arginine-based formulation reported improvements in intimate comfort. The relevance to LibiTight is L-arginine's mechanism: it acts as a nitric oxide precursor, supporting local circulation in tissue — the action LibiTight delivers in topical form.
Note: this study tested an oral combination supplement, not topical L-arginine. The mechanism (nitric oxide precursor supporting local circulation) is the same; LibiTight applies it through topical delivery to vaginal tissue.
Published in PubMed · PMID 14671668
View studyWhat's next
Whether you're ready to find LibiTight, want to understand the formula, or have a question — pick what fits.
See where LibiTight is sold and how to ask your pharmacist.
Where to buyThe five actives in LibiTight, explained in detail.
IngredientsQuestions about the research or the formula? Reach us on WhatsApp.
Open WhatsApp